ABT · 10-Q · 2026Q2 · Full report
Product Launch and Transition
ABBOTT LABORATORIES · 2026-07-28 · Importance 36 · Surprise 50 · No source text
Abbott announced in May 2026 that it secured CE Mark for Libre Duo, a dual glucose-ketone biowearable sensor. The launch expands Abbott’s diabetes-care sensor portfolio beyond its existing continuous glucose monitoring systems. The product is positioned for international commercialization through the European conformity-mark pathway. Diabetes Care sales were already growing 8.2% excluding foreign exchange in the first six months, supported by CGM demand in the U.S. and internationally.
Key facts
- Abbott secured CE Mark for Libre Duo, its dual glucose-ketone biowearable sensor, in May 2026.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Abbott secured CE Mark for Libre Duo, its dual glucose-ketone biowearable sensor, in May 2026. |